Table 1 Demographic and clinical data of study population
From: Thoracentesis under clopidogrel is not associated with excessive bleeding events: a cohort study
Clopidogrel treatment (n = 88) | No clopidogrel treatment (n = 169) | p value | |
|---|---|---|---|
Age (mean ± SD) | 77.5 ± 11 | 76 ± 14 | 0.33 |
Sex (male) | 53 (60%) | 82 (48%) | 0.09 |
Charlson comorbidity score (median, IQR) | 2 (1–3) | 1 (0–2) | < 0.001 |
Concomitant drug use | |||
Aspirin | 41 (46%) | 9 (5%) | < 0.001 |
Warfarin | 2 (2.3%) | 3 (1.7%) | 1 |
DOAC | 2 (2.3%) | 4 (2.4%) | 1 |
Other bleeding risk factors | |||
Platelet count (mean ± SD) | 249 ± 124 | 259 ± 129 | 0.72 |
Renal failure (n) | 26 | 15 | < 0.001 |
US guidance | 22 (25%) | 57 (34%) | 0.15 |